2017 Fiscal Year Final Research Report
Elucidation of pathogenesis of drug-induced immune diseases caused by activation of inflammasome
| Project/Area Number |
16K15146
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Environmental and hygienic pharmacy
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Keywords | 薬剤誘発性免疫疾患 / インフラマソーム / 炎症性サイトカイン / NLRPファミリー分子 / 薬剤副作用 |
|---|
| Outline of Final Research Achievements |
Drug-induced immune diseases, such as interstitial pneumonia caused by the anticancer drug Gefitinib, are considered to be fatal and severe side effects and important problems, which must be solved in the field of pharmaceutical health science. However, the actual cause of the diseases is not yet well understood. Inflammasomes, intracellular receptors recognizing pathogens and foreign materials, induce inflammation and cell death and have recently been shown to be the cause of various immune diseases. In this study, we revealed that several drugs activate inflammasomes composed of NLRP family molecules, and that drug-induced immune diseases may be partially caused by abnormal promotion of immune response through the activation of inflammasomes.
|
| Free Research Field |
分子生物学
|
